病毒学报

[1]Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA A Cancer J Clin, 2018, 68(6):394-424. DOI:10. 3322/caac. 21492.

[2]Lampertico P, Agarwal K, Berg T, et al. EASL 2017Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2):370-398. DOI:10. 1016/j. jhep. 2017. 03. 021.

[3]朱丽芬，周佩，蔡海奕，等.慢性乙型肝炎功能性治愈生物标志物的过去、现状与未来[J].病毒学报，2025,41(2):279-290. DOI:10. 13242/j. cnki.bingduxuebao. 250006.

[4]Kim GA, Choi SW, Han S, et al. Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B[J]. Clin Mol Hepatol,2024, 30(4):793-806. DOI:10. 3350/cmh. 2024. 0252.

[5]Choi WM, Yip TC, Kim WR, et al. Chronic hepatitis B baseline viral load and on-treatment liver cancer risk:a multinational cohort study of HBeAg-positive patients[J]. Hepatology, 2024, 80(2):428-439. DOI:10. 1097/HEP. 0000000000000752.

[6]Ratnaparkhi MM, Vyawahare CR, Gandham NR.Hepatitis B virus genotype distribution and mutation patterns:Insights and clinical implications for hepatitis B virus positive patients[J]. World J Exp Med, 2025, 15(2):102395. DOI:10. 5493/wjem. v15. i2. 102395.

[7]Belaiba Z, Ayouni K, Gdoura M, et al. Whole genome analysis of hepatitis B virus before and during long-term therapy in chronic infected patients:Molecular characterization, impact on treatment and liver disease progression[J]. Front Microbiol, 2022, 13:1020147.DOI:10. 3389/fmicb. 2022. 1020147.

[8]Liaw YF. Perspectives on outcome prediction in patients with chronic hepatitis B virus infection[J].Gastro Hep Adv, 2023, 3(2):162-166. DOI:10. 1016/j. gastha. 2023. 11. 002.

[9]Hosaka T, Suzuki F, Kobayashi M, et al. Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues[J]. Aliment Pharmacol Ther, 2019,49(4):457-471. DOI:10. 1111/apt. 15108.

[10]Xu X, Wu C, Lou Z, et al. Changing incidence of hepatitis B and persistent infection risk in adults:a population-based follow-up study from 2011 in China[J]. BMC Public Health, 2023, 23(1):256. DOI:10. 1186/s12889-023-15130-y.

[11]Zheng Z, Lin X, Huang Y, et al. Trends and ageperiod-cohort effect on incidence of hepatitis B from2008 to 2022 in Guangzhou, China[J]. Sci Rep, 2024,14(1):13370. DOI:10. 1038/s41598-024-63796-0.

[12]中华医学会肝病学分会，中华医学会感染病学分会.慢性乙型肝炎防治指南（2022年版）[J].传染病信息，2023, 36(1):1-17. DOI:10. 3969/j. issn. 1007-8134. 2023. 01. 01.

[13]You H, Kong Y, Hou J, et al. Female gender lost protective effect against disease progression in elderly patients with chronic hepatitis B[J]. Sci Rep, 2016, 6:37498. DOI:10. 1038/srep37498.

[14]Wang SH, Chen PJ, Yeh SH. Gender disparity in chronic hepatitis B:Mechanisms of sex hormones[J]. J Gastroenterol Hepatol, 2015, 30(8):1237-1245. DOI:10. 1111/jgh. 12934.

[15]Wasityastuti W, Yano Y, Ratnasari N, et al. Protective effects of HLA-DPA1/DPB1 variants against Hepatitis B virus infection in an Indonesian population[J]. Infect Genet Evol, 2016, 41:177-184. DOI:10. 1016/j.meegid. 2016. 03. 034.

[16]He Q, Huang Y, Zhang L, et al. Association between vitamin D receptor polymorphisms and hepatitis B virus infection susceptibility:a meta-analysis study[J].Gene, 2018, 645:105-112. DOI:10. 1016/j.gene. 2017. 12. 027.

[17]Huang X, Li H, Wang J, et al. Genetic polymorphisms in Toll-like receptor 3 gene are associated with the risk of hepatitis B virus-related liver diseases in a Chinese population[J]. Gene, 2015, 569(2):218-224. DOI:10. 1016/j. gene. 2015. 05. 054.

[18]Sun Y, Lu Y, Li T, et al. Interferon gamma+874T/a polymorphism increases the risk of hepatitis virus-related diseases:evidence from a meta-analysis[J]. PLoS One,2015, 10(5):e0121168. DOI:10. 1371/journal.pone. 0121168.

[19]Zhang W, He H, Zang M, et al. Genetic features of aflatoxin-associated hepatocellular carcinoma[J].Gastroenterology, 2017, 153(1):249-262. e2. DOI:10. 1053/j. gastro. 2017. 03. 024.

[20]Bandopadhyay M, Bharadwaj M. Exosomal miRNAs in hepatitis B virus related liver disease:a new hope for biomarker[J]. Gut Pathog, 2020, 12:23. DOI:10. 1186/s13099-020-00353-w.

[21]Kareem RA, Sameer HN, Athab ZH, Adil M, Yaseen A, Allela OQB. A review of the relationship between type 2 diabetes mellitus and different stages of hepatitis B infection(HCC, CHB, OBI)[J]. Microb Pathog,2025 , 206:107748. DOI:10. 1016/j.micpath. 2025. 107748.

[22]Li J, Xu L, Rui F, et al. Type 2 diabetes mellitus as an independent predictor of significant fibrosis in treatmentna?ve chronic hepatitis B patients with concurrent hepatic steatosis[J]. Hepatology, 2025:DOI:10. 1097/HEP. 0000000000001442 DOI:10. 1097/HEP. 0000000000001442.

[23]Liu X, Wang X. The prognosis of patients with comorbid diabetes and hepatitis B and strategies for improving outcome[J]. Am J Med Sci, 2025, 369(5):638-641. DOI:10. 1016/j. amjms. 2024. 12. 011.

[24]Tong XC, Liu K, Huang ZY, et al. Obesity has causal effects on chronic hepatitis B but CHB has no causal effect on obesity:evidence from a Mendelian randomization study[J]. Crit Public Health, 2025, 35(1):2521449. DOI:10. 1080/09581596. 2025. 2521449.

[25]Fan R, Niu J, Ma H, et al. Association of central obesity with hepatocellular carcinoma in patients with chronic hepatitis B receiving antiviral therapy[J].Aliment Pharmacol Ther, 2021, 54(3):329-338. DOI:10. 1111/apt. 16469.

[26]Zhu Q, Su C, Li M, et al. Impact of metabolic dysfunction-associated fatty liver disease of varying severity on antiviral treatment outcomes and clinical prognosis in patients with chronic hepatitis B:a systematic review and meta-analysis[J]. Infect Dis Ther, 2025, 14(8):1599-1617. DOI:10. 1007/s40121-025-01189-0.

[27]Zheng Q, Zou B, Wu Y, et al. Systematic review with meta-analysis:prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B[J]. Aliment Pharmacol Ther, 2021, 54(9):1100-1109. DOI:10. 1111/apt. 16595.

[28]Huang SC, Liu CJ. Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease:Challenges and perspectives[J]. Clin Mol Hepatol,2023, 29(2):320-331. DOI:10. 3350/cmh. 2022. 0422.

[29]Kwok TY, Hui RW, Mao X, et al. Cigarette smoking is associated with lower chance of hepatitis B surface antigen seroclearance and altered host immunity[J]. J Viral Hepat, 2024, 31(12):847-856. DOI:10. 1111/jvh. 14007.

[30]Chuang SC, Lee YA, Wu GJ, et al. Alcohol consumption and liver cancer risk:a meta-analysis[J].Cancer Causes Control, 2015, 26(9):1205-1231.DOI:10. 1007/s10552-015-0615-3.

[31]Jose-Abrego A, Rivera-I?iguez I, Torres-Reyes LA, et al. Anti-hepatitis B virus activity of food nutrients and potential mechanisms of action[J]. Ann Hepatol, 2023,28(4):100766. DOI:10. 1016/j. aohep. 2022. 100766.

[32]Wang YY, Yao YQ, Sun Y, et al. Personalized dietary self-management and its influence on disease progression in chronic hepatitis B[J]. J Nutr Metab, 2025, 2025:5585004. DOI:10. 1155/jnme/5585004.

[33]Seto WK, Lai CL, Ip PPC, et al. A large population histology study showing the lack of association between ALT elevation and significant fibrosis in chronic hepatitis B[J]. PLoS One, 2012, 7(2):e32622. DOI:10. 1371/journal. pone. 0032622.

[34]Mason WS, Gill US, Litwin S, et al. HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant[J].Gastroenterology, 2016, 151(5):986-998. e4. DOI:10. 1053/j. gastro. 2016. 07. 012.

[35]中华医学会肝病学分会肝炎学组，中华肝脏病杂志编辑委员会，胡鹏，等.加速消除乙型肝炎病毒感染：扩大预防和治疗专家建议[J].中华肝脏病杂志，2024,32(6):497-503.

[36]肖荣，肖丽萍，王美华，等.血清炎症因子及免疫功能指标在慢性乙型肝炎病毒感染中的应用进展[J].病毒学报，2025, 41(5):1600-1608. DOI:10. 13242/j.cnki. bingduxuebao. 250208.

[37]王琪，王晶. HIF-1α,β2GPI和Th17及其相关因子在乙型肝炎病毒感染相关性肝癌中的预测价值[J/OL].病毒学报，1-7[2026-03-02]. https：//link. cnki. net/urlid/11. 1865. R. 20251226. 1132. 002.

[38]Su TH, Peng CY, Chang SH, et al. Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis[J]. J Formos Med Assoc, 2022, 121(3):703-711. DOI:10. 1016/j. jfma. 2021. 08. 003.

[39]Xia Y, Zhang Y, Shen M, et al. Golgi protein 73 and its diagnostic value in liver diseases[J]. Cell Prolif,2019, 52(2):e12538. DOI:10. 1111/cpr. 12538.

[40]Jia J, Shang J, Tang H, et al. Long-term outcomes in Chinese patients with chronic hepatitis B receiving nucleoside/nucleotide analogue therapy in real-world clinical practice:5-year results from the EVOLVE study[J]. Antivir Ther, 2020, 25(6):293-304. DOI:10. 3851/IMP3372.

[41]He MW, Cui L, Chen DD, et al. Efficacy and safety of switching from entecavir to tenofovir alafenamide in chronic hepatitis B patients with low-level viremia:a real-world 48-week extension study[J]. Antimicrob Agents Chemother, 2025, 69(3):e01827-e01824.DOI:10. 1128/aac. 01827-24.

[42]Yip TC, Wong VW, Chan HL, et al. Tenofovir is associated with lower risk of hepatocellular carcinoma than entecavir in patients with chronic HBV infection in China[J]. Gastroenterology, 2020, 158(1):215-225.e6. DOI:10. 1053/j. gastro. 2019. 09. 025.

[43]Ashuo A, Liu J, Yuan Z, et al. Interferon-α for immune modulation in chronic hepatitis B toward functional cure[J]. Viruses, 2025, 17(10):1358.DOI:10. 3390/v17101358.

[44]Hu Q, Zhang X, Cao X, et al. Long-term effects of peginterferon-based therapy versus nucleos(t)ide analogue monotherapy in non-cirrhotic HBeAg-positive chronic hepatitis B patients[J]. Antiviral Res, 2025,240:106192. DOI:10. 1016/j. antiviral. 2025. 106192.

[45]Fanning GC, Zoulim F, Hou J, et al. Therapeutic strategies for hepatitis B virus infection:towards a cure[J]. Nat Rev Drug Discov, 2019, 18(11):827-844.DOI:10. 1038/s41573-019-0037-0.

[46]Chen S, Zhou J, Wu X, et al. Liver fibrosis showed a two-phase regression rate during long-term anti-HBV therapy by three-time biopsies assessments[J]. Hepatol Int, 2024, 18(3):904-916. DOI:10. 1007/s12072-024-10643-z.

[47]Yuen MF, Locarnini S, Lim TH, et al. Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB[J]. J Hepatol, 2022, 77(5):1287-1298. DOI:10. 1016/j. jhep. 2022. 07. 010.

[48]Yuen M-F, Berliba E, Sukeepaisarnjaroen W, et al.Repeat dosing of the GalNac-siRNA AB-729 in subjects with chronic hepatitis B results in robust and sustained HBsAg suppression[J]. J Hepatol, 2021, 75:S203.https：//www. natap. org/2021/EASL/EASL_40. htm

[49]Yuen MF, Lim YS, Yoon KT, et al. VIR-2218(elebsiran)plus pegylated interferon-Alfa-2a in participants with chronic hepatitis B virus infection:a phase 2 study[J]. Lancet Gastroenterol Hepatol, 2024,9(12):1121-1132. DOI:10. 1016/S2468-1253(24)00237-1.

[50]Zheng S, Cao H, Zhang M, et al. A potent GalNAcsiRNA drug, RBD1016, leads to sustained HBsAg reduction and seroconversion in mouse models of HBV infection[J]. Mol Ther Nucleic Acids, 2025, 36(3):102627. DOI:10. 1016/j. omtn. 2025. 102627.

[51]Zhang J, Li J, Wu L, et al. A double-blind, placebocontrolled, single-ascending dose study to evaluate the safety, tolerability, and pharmacokinetics of HT-101,an RNAi therapeutic targeting HBV infection[J]. Clin Pharmacol Drug Dev, 2025, 14(10):754-763. DOI:10. 1002/cpdd. 1569.

[52]Hui RW, Mak LY, Seto WK, et al. RNA interference as a novel treatment strategy for chronic hepatitis B infection[J]. Clin Mol Hepatol, 2022, 28(3):408-424. DOI:10. 3350/cmh. 2022. 0012.

[53]Yuen MF, Lim SG, Plesniak R, et al. Efficacy and safety of bepirovirsen in chronic hepatitis B infection[J].N Engl J Med, 2022, 387(21):1957-1968. DOI:10. 1056/NEJMoa2210027.

[54]Mak LY, Hui RW, Fung J, et al. Bepirovirsen(GSK3228836)in chronic hepatitis B infection:an evaluation of phase II progress[J]. Expert Opin Investig Drugs, 2023, 32(11):971-983. DOI:10. 1080/13543784. 2023. 2277389.

[55]Gane EJ, Yuen MF, Wang W, et al. Safety and antiviral activity ofAHB-137, a novel antisense oligonucleotide, in healthy volunteersand subjects with chronic hepatitis B[J]. J Hepatol, 2024, 80:S86-S86.https：//www. natap. org/2024/EASL/EASL_113. htm

[56]Ren Q, Liu X, Luo Z, et al. Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate(GLS4)[J]. Bioorg Med Chem, 2017, 25(3):1042-1056. DOI:10. 1016/j. bmc. 2016. 12. 017.

[57]Zhang H, Wang F, Zhu X, et al. Antiviral activity and pharmacokinetics of the hepatitis B virus(HBV)capsid assembly modulator GLS4 in patients with chronic HBV infection[J]. Clin Infect Dis, 2021, 73(2):175-182.DOI:10. 1093/cid/ciaa961.

[58]Zhang M, Gao Y, Kong F, et al. Efficacy and safety of GLS4 with entecavir vs entecavir alone in chronic hepatitis B patients:a multicenter clinical trial[J]. J Infect, 2025, 90(3):106446. DOI:10. 1016/j.jinf. 2025. 106446.

[59]Wu M, Mai J, Zhang H, et al. Safety,pharmacokinetics, and antiviral efficacy of the novel capsid assembly modulator GST-HG141 in patients with chronic hepatitis B:a phase 1 trial with a randomized,placebo-controlled design[J]. Virol J, 2024, 21(1):328. DOI:10. 1186/s12985-024-02584-8.

[60]Hou JL, Ding YH, Niu JQ,et al. ALG-000184, a Capsid Assembly Modulator, Demonstrates Superior Antiviral Activity in Combination with Entecavir Compared to Entecavir in HBeAg Positive Subjects with Chronic Hepatitis B infection[C]. APASL,2023.https：//aligos. com/wp-content/uploads/2023/02/3_ALG-000184_APASL-2023_Part-4-C1-2_Prof.-Hou_Clinical-Oral-Presentation. pdf.

[61]Bazinet M, Pantea V, Cebotarescu V, et al. Safety and efficacy of REP 2139 and pegylated interferon Alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection(REP 301 and REP 301-LTF):a non-randomised, open-label, phase2 trial[J]. Lancet Gastroenterol Hepatol, 2017, 2(12):877-889. DOI:10. 1016/S2468-1253(17)30288-1.

[62]Bazinet M, Pantea V, Placinta G, et al. Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon Alfa-2a in patients with chronic HBV infection Na?ve to nucleos(t)ide therapy[J]. Gastroenterology, 2020, 158(8):2180-2194. DOI:10. 1053/j. gastro. 2020. 02. 058.

[63]Hu Y, Sun F, Yuan Q, et al. Discovery and preclinical evaluations of GST-HG131, a novel HBV antigen inhibitor for the treatment of chronic hepatitis B infection[J]. Bioorg Med Chem Lett, 2022, 75:128977. DOI:10. 1016/j. bmcl. 2022. 128977.

[64]Li X, Liu Y, Yao H, et al. Safety, tolerability, and pharmacokinetics of the novel hepatitis B virus expression inhibitor GST-HG131 in healthy Chinese subjects:a first-in-human single-and multiple-dose escalation trial[J]. Antimicrob Agents Chemother,2022, 66(5):e00094-e00022. DOI:10. 1128/aac. 00094-22.

[65]Qi X, Li W. Unlocking the secrets to human NTCP structure[J]. Innovation, 2022, 3(5):100294. DOI:10. 1016/j. xinn. 2022. 100294.

[66]Bogomolov P, Alexandrov A, Voronkova N, et al.Treatment of chronic hepatitis D with the entry inhibitor myrcludex B:First results of a phase Ib/IIa study[J]. J Hepatol, 2016, 65(3):490-498. DOI:10. 1016/j.jhep. 2016. 04. 016.

[67]Zhao K, Liu S, Chen Y, et al. Upregulation of HBV transcription by sodium taurocholate cotransporting polypeptide at the postentry step is inhibited by the entry inhibitor Myrcludex B[J]. Emerg Microbes Infect,2018, 7(1):186. DOI:10. 1038/s41426-018-0189-8.

[68]Mak LY, Seto WK, Yuen MF. Novel antivirals in clinical development for chronic hepatitis B infection[J].Viruses, 2021, 13(6):1169. DOI:10. 3390/v13061169.

[69]Wang X, Chi X, Zhang Y, et al. LBP-24 Safety and efficacy of anti-pre-S1 domain monoclonal antibody(HH-003)treatment in patients with co-infection of chronic hepatitis B virus(HBV)and hepatitis D virus(HDV):a single center, open-label, phase 2 trial[J]. J Hepatol, 2023, 78:S117. DOI:10. 1016/S0168-8278(23)00606-2.

[70]Erken R, Andre P, Roy E, et al. Farnesoid X receptor agonist for the treatment of chronic hepatitis B:a safety study[J]. J Viral Hepat, 2021, 28(12):1690-1698.DOI:10. 1111/jvh. 13608.

[71]Sekiba K, Otsuka M, Ohno M, et al. Inhibition of HBV transcription from cccDNA with nitazoxanide by targeting the HBx-DDB1 interaction[J]. Cell Mol Gastroenterol Hepatol, 2019, 7(2):297-312. DOI:10. 1016/j. jcmgh. 2018. 10. 010.

[72]Cheng ST, Hu JL, Ren JH, et al. Dicoumarol, an NQO1 inhibitor, blocks cccDNA transcription by promoting degradation of HBx[J]. J Hepatol, 2021, 74(3):522-534. DOI:10. 1016/j. jhep. 2020. 09. 019.

[73]Martín-Alonso S, Kang D, Martínez Del Río J, et al.Novel RNase H inhibitors blocking RNA-directed strand displacement DNA synthesis by HIV-1 reverse transcriptase[J]. J Mol Biol, 2022, 434(7):167507.DOI:10. 1016/j. jmb. 2022. 167507.

[74]Chauhan R, Li Q, Woodson ME, et al. Efficient inhibition of hepatitis B virus(HBV)replication and cccDNA formation by HBV ribonuclease H inhibitors during infection[J]. Antimicrob Agents Chemother,2021, 65(12):e01460-e01421. DOI:10. 1128/AAC. 01460-21.

[75]Jang JH, Kim JW, Jeong SH, et al. Clevudine for chronic hepatitis B:antiviral response, predictors of response, and development of myopathy[J]. J Viral Hepat, 2011, 18(2):84-90. DOI:10. 1111/j. 1365-2893. 2010. 01281. x.

[76]Squires KE, Mayers DL, Bluemling GR, et al. ATI-2173, a novel liver-targeted non-chain-terminating nucleotide for hepatitis B virus cure regimens[J].Antimicrob Agents Chemother, 2020, 64(9):e00836-e00820. DOI:10. 1128/AAC. 00836-20.

[77]Squires KE, Ogilvie L, Jucov A, et al. A randomized phase 1b trial of the active site polymerase inhibitor nucleotide ATI-2173 in patients with chronic hepatitis B virus infection[J]. J Viral Hepat, 2023, 30(1):19-28.DOI:10. 1111/jvh. 13753.

[78]Janssen HLA, Brunetto MR, Kim YJ, et al. Safety,efficacy and pharmacodynamics of vesatolimod(GS-9620)in virally suppressed patients with chronic hepatitis B[J]. J Hepatol, 2018, 68(3):431-440.DOI:10. 1016/j. jhep. 2017. 10. 027.

[79]Korolowizc KE, Li B, Huang X, et al. Liver-targeted toll-like receptor 7 agonist combined with entecavir promotes a functional cure in the woodchuck model of hepatitis B virus[J]. Hepatol Commun, 2019, 3(10):1296-1310. DOI:10. 1002/hep4. 1397.

[80]Mackman RL, Mish M, Chin G, et al. Discovery of GS-9688(selgantolimod)as a potent and selective oral toll-like receptor 8 agonist for the treatment of chronic hepatitis B[J]. J Med Chem, 2020, 63(18):10188-10203. DOI:10. 1021/acs. jmedchem. 0c00100.

[81]Paulsen D, Weber O, Ruebsamen-Schaeff H, et al.AIC649 induces a bi-phasic treatment response in the woodchuck model of chronic hepatitis B[J]. PLoS One,2015, 10(12):e0144383. DOI:10. 1371/journal.pone. 0144383.

[82]Gane E, Verdon DJ, Brooks AE, et al. Anti-PD-1blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B:a pilot study[J]. J Hepatol, 2019, 71(5):900-907.DOI:10. 1016/j. jhep. 2019. 06. 028.

[83]Al-Mahtab M, Akbar SMF, Yoshida O, et al.Antiviral response across genotypes after treatment of chronic hepatitis B patients with the therapeutic vaccine NASVAC or pegylated interferon[J]. Vaccines, 2023,11(5):962. DOI:10. 3390/vaccines11050962.

[84]Tak WY, Chuang WL, Chen CY, et al. Phase Ib/IIa randomized study of heterologous ChAdOx1-HBV/MVA-HBV therapeutic vaccination(VTP-300)as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB[J]. J Hepatol,2024, 81(6):949-959. DOI:10. 1016/j.jhep. 2024. 06. 027.

[85]Xie P, Huang Y, Yang L, et al. 346 Enhanced antitumor activity of HBsAg specific TCR-T(SCG101)in hepatitis B virus(HBV)related hepatocellular carcinoma(HCC)by preventing T cell exhaustion through PD-1/PD-L1 axis blockade[C]//Regular and Young Investigator Award Abstracts. BMJ Publishing Group Ltd, 2022:A364-A364.. DOI:10. 1136/jitc-2022-sitc2022. 0346.

[86]Bourgeois S, Lim YS, Gane EJ, et al. SAT437 IMCI109V, a novel T cell receptor(TCR)bispecific(ENVxCD3)designed to eliminate HBV-infected hepatocytes in chronic HBV patients:initial data from a first-in-human study[J]. J Hepatol, 2022, 77:S872-S873. DOI:10. 1016/S0168-8278(22)02039-6.

[87]Gane EJ, Jucov A, Dobryanksa M, et al. OS-031Safety and antiviral activity of short-duration combinations of the investigational small interfering ribonucleic acid VIR-2218 with the neutralizing, vaccinal monoclonal antibody VIR-3434:post-treatment followup from the Phase 2 MARCH trial[J]. J Hepatol,2023, 78:S34-S35. DOI:10. 1016/S0168-8278(23)00488-9.

[88]Gopalakrishna H, Ghany MG. Perspective on emerging therapies to achieve functional cure of chronic hepatitis B[J]. Curr Hepatol Rep, 2024, 23(2):241-252. DOI:10. 1007/s11901-024-00652-9.

[89]Zeng W, Zheng L, Li Y, et al. Engineered extracellular vesicles for delivering functional Cas9/gRNA to eliminate hepatitis B virus cccDNA and integration[J].Emerg Microbes Infect, 2024, 13(1):2284286. DOI:10. 1080/22221751. 2023. 2284286.

[90]Yang YC, Chen YH, Kao JH, et al. Permanent inactivation of HBV genomes by CRISPR/Cas9-mediated non-cleavage base editing[J]. Mol Ther Nucleic Acids, 2020, 20:480-490. DOI:10. 1016/j.omtn. 2020. 03. 005.

[91]Kostyushev D, Kostyusheva A, Brezgin S, et al.Depleting hepatitis B virus relaxed circular DNA is necessary for resolution of infection by CRISPR-Cas9[J]. Mol Ther Nucleic Acids, 2023, 31:482-493.DOI:10. 1016/j. omtn. 2023. 02. 001.

[92]Tune Therapeutics, Inc. Phase 1b Multicenter, OpenLabel Study to Assess the Safety, Tolerability,Pharmacokinetics, and Pharmacodynamics of Tune-401in Participants With Chronic Hepatitis B Infection[EB/OL].(2024-11-04)[2025-12-23]. https：//clinicaltrials. gov/study/NCT06671093

[93]Wang L, Ji D, Liu X, et al. Recent progress of triplex DNA formation and its applications[J]. J Med Chem,2025, 68(5):5055-5074. DOI:10. 1021/acs.jmedchem. 4c02518.引用本文：刘慧敏,朴红心,王童舒,等.慢性乙型肝炎患者发病和疾病进展相关因素及其抗病毒药物治疗的临床应用进展[J].病毒学报, XXXX, XX(XX):1-11.